Limaye S Limaye V.

Clinical Characteristics of Myositis Associated with Graft-Versus-Host Disease.

Curr Rheumatol Rep. 2021; 23: 30https://doi.org/10.1007/s11926-021-00996-xView in Article Scopus (0) PubMed Crossref Google ScholarSchoemans HM Lee SJ Ferrara JL Wolff D Levine JE Schultz KR et al.

EBMT−NIH−CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment.

Bone Marrow Transplant. 2018; 53: 1401-1415https://doi.org/10.1038/s41409-018-0204-7View in Article Scopus (65) PubMed Crossref Google ScholarStevens AM.

Polymyositis as a manifestation of chronic graft-versus-host disease.

Rheumatology. 2003; 42: 34-39https://doi.org/10.1093/rheumatology/keg025View in Article Scopus (75) PubMed Crossref Google ScholarNew-Tolley J Smith C Koszyca B Otto S Maundrell A Bardy P et al.

Inflammatory myopathies after allogeneic stem cell transplantation.

Muscle Nerve. 2018; 58: 790-795https://doi.org/10.1002/mus.26341View in Article Scopus (6) PubMed Crossref Google ScholarKoeppen S Thirugnanasambanthan A Koldehoff M.

Neuromuscular complications after hematopoietic stem cell transplantation.

Support Care Cancer. 2014; 22: 2337-2341https://doi.org/10.1007/s00520-014-2225-0View in Article Scopus (12) PubMed Crossref Google ScholarOda K Nakaseko C Ozawa S Nishimura M Saito Y Yoshiba F et al.

Fasciitis and myositis: An analysis of muscle-related complications caused by chronic GVHD after allo-SCT.

Bone Marrow Transplant. 2009; 43: 159-167https://doi.org/10.1038/bmt.2008.297View in Article Scopus (28) PubMed Crossref Google ScholarWaller EK Miklos D Cutler C Arora M Jagasia MH Pusic I et al.

Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.

Biol Blood Marrow Transpl. 2019; 25: 2002-2007https://doi.org/10.1016/j.bbmt.2019.06.023View in Article Scopus (17) PubMed Abstract Full Text Full Text PDF Google ScholarAllenbach Y Benveniste O.

Acquired necrotizing myopathies.

Curr Opin Neurol. 2013; 26: 554-560https://doi.org/10.1097/WCO.0b013e328364e9d9View in Article Scopus (43) PubMed Crossref Google ScholarMammen AL Allenbach Y Stenzel W Benveniste O Allenbach DY Benveniste DO et al.

239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December 2018.

Neuromuscul. Disord. 2020; 30https://doi.org/10.1016/j.nmd.2019.10.005View in Article Scopus (17) PubMed Abstract Full Text Full Text PDF Google ScholarOddis CV. Reed AM Aggarwal R Rider LG Ascherman DP Levesque MC et al.

Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial.

Arthritis Rheum. 2013; 65: 314-324https://doi.org/10.1002/art.37754View in Article Scopus (327) PubMed Crossref Google ScholarTjärnlund A Tang Q Wick C Dastmalchi M Mann H Studýnková JT et al.

Abatacept in the treatment of adult dermatomyositis and polymyositis: A randomised, phase IIb treatment delayed-start trial.

Ann Rheum Dis. 2018; 77: 55-62https://doi.org/10.1136/annrheumdis-2017-211751View in Article Scopus (43) PubMed Crossref Google ScholarMiklos D Cutler CS Arora M Waller EK Jagasia M Pusic I et al.

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.

Blood. 2017; 130: 2243-2250https://doi.org/10.1182/blood-2017-07-793786View in Article Scopus (140) PubMed Crossref Google ScholarGolec S Rabinovich E Cohen M Baer L Chamoun K Lima M de

Refractory inflammatory myopathy in hematopoietic stem cell transplant patients with chronic graft-versus-host disease: report of two cases.

Hematol Transfus Cell Ther. 2019; 41: 268-271https://doi.org/10.1016/j.htct.2019.01.002View in Article Scopus (2) PubMed Crossref Google ScholarO'Brien S Hillmen P Coutre S Barr PM Fraser G Tedeschi A et al.

Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.

Clin Lymphoma Myeloma Leuk. 2018; 18: 648-657.e15https://doi.org/10.1016/j.clml.2018.06.016View in Article Scopus (24) PubMed Abstract Full Text Full Text PDF Google ScholarRhodes JM LoRe 3rd, VA Mato AR Chong EA Barrientos JC Gerson JN et al.

Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes.

Clin Lymphoma Myeloma Leuk. 2020; 20: 438-444.e1https://doi.org/10.1016/j.clml.2020.02.001View in Article Scopus (5) PubMed Abstract Full Text Full Text PDF Google ScholarPenack O Marchetti M Ruutu T Aljurf M Bacigalupo A Bonifazi F et al.

Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.

Lancet Haematol. 2020; 7: e157-e167https://doi.org/10.1016/s2352-3026(19)30256-xView in Article Scopus (0) PubMed Abstract Full Text Full Text PDF Google ScholarSarantopoulos S Cardones AR Sullivan KM.

How I treat refractory chronic graft-versus-host disease.

Blood. 2019; 133: 1191-1200https://doi.org/10.1182/blood-2018-04-785899View in Article Scopus (22) PubMed Crossref Google ScholarMontillo M O'Brien S Tedeschi A Byrd JC Dearden C Gill D et al.

Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study.

Blood Cancer J. 2017; 7: e524https://doi.org/10.1038/bcj.2017.5View in Article Scopus (19) PubMed Crossref Google ScholarRogers KA Ruppert AS Bingman A Andritsos LA Awan FT Blum KA et al.

Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.

Leukemia. 2016; 30: 346-350https://doi.org/10.1038/leu.2015.273View in Article Scopus (44) PubMed Crossref Google ScholarHutcheson J Vanarsa K Bashmakov A Grewal S Sajitharan D Chang BY et al.

Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus.

Arthritis Res Ther. 2012; 14: R243https://doi.org/10.1186/ar4086View in Article Scopus (65) PubMed Crossref Google ScholarSchliffke S Akyüz N Ford CT Mährle T Thenhausen T Krohn-Grimberghe A et al.

Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia.

Leukemia. 2016; 30: 2232-2234https://doi.org/10.1038/leu.2016.157View in Article Scopus (14) PubMed Crossref Google ScholarDubovsky JA Beckwith KA Natarajan G Woyach JA Jaglowski S Zhong Y et al.

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

Blood. 2013; 122: 2539-2549https://doi.org/10.1182/blood-2013-06-507947View in Article Scopus (449) PubMed Crossref Google ScholarVitale C Ahn IE Sivina M Ferrajoli A Wierda WG Estrov Z et al.

Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.

Haematologica. 2016; 101: e254-e258https://doi.org/10.3324/haematol.2015.138289View in Article Scopus (28) PubMed Crossref Google Scholar